Adaptive Medical

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company's proprietary Immune Medicine Platform uses high-throughput sequencing and computational biology to read and translate the genetic code of T-cell and B-cell receptors. Its commercial products include clonoSEQ, the first FDA-cleared test for minimal residual disease (MRD) in certain blood cancers, and T-Detect, a T-cell-based diagnostic. Adaptive also partners with major pharmaceutical companies, such as Pfizer and Microsoft, to develop TCR-based cellular therapies and identify novel drug targets across oncology, autoimmune, and infectious diseases.